X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Alexon pharmaceuticals brings updates on its FY18 Earnings Guidance

Content Team by Content Team
5th March 2018
in Market Moves

Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday. The company provided earnings per share guidance of $6.60-6.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.03

Alexion Pharmaceuticals (NASDAQ:ALXN) updated its FY18 earnings guidance on Thursday. The company provided earnings per share guidance of $6.60-6.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.03. The company issued revenue guidance of $3.85-3.95 billion, compared to the consensus revenue estimate of $4.06 billion.

A number of equities research analysts recently issued reports on the stock. ValuEngine cut shares of Alexion Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday. Deutsche Bank set a $161.00 price target on shares of Alexion Pharmaceuticals and gave the company a buy rating in a research note on Friday, February 9th. BMO Capital Markets lifted their price target on shares of Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an outperform rating in a research note on Friday, February 9th.

Citigroup dropped their price target on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a buy rating on the stock in a research note on Friday, February 9th. Finally, Stifel Nicolaus reissued a buy rating and issued a $151.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, February 9th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $152.77.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $2.81 during mid-day trading on Friday, hitting $117.92. 1,340,000 shares of the stock traded hands, compared to its average volume of 2,050,000. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10. The firm has a market cap of $26,140.00, a PE ratio of 54.34, a price-to-earnings-growth ratio of 1.09 and a beta of 1.13. Alexion Pharmaceuticals has a 1 year low of $96.18 and a 1 year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The company’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 EPS. analysts expect that Alexion Pharmaceuticals will post 6.12 EPS for the current fiscal year.

In other news, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30.

Following the transaction, the senior vice president now directly owns 32,635 shares in the company, valued at approximately $3,826,780.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 31,253 shares of company stock worth $3,656,229. Corporate insiders own 4.35% of the company’s stock.

Previous Post

Shire announce its Pivotal study for Hereditary Angioedema at 2018 AAAAI/WAO Joint Congress

Next Post

Personalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018

Related Posts

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
EMA Advises Recall of AbbVie, Biogen MS Drug
Market Moves

No Rush In Indian Generic Drug Firms To Launch COVID Products

16th July 2022
Market Moves

Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

8th April 2022
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Market Moves

Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

29th January 2022
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Indian Pharma Industry To Grow By 9-11% In FY22- ICRA

7th January 2022
Next Post

Personalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018

Latest News

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In